Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
Discontinued
Reference number: GID-TA10186
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations.
However, following on from information received from the company regarding the recent results for the Phase III MYSTIC trial, the timelines for this appraisal are to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.